Scarica l'app Stockscreener
11.85
5.24%
0.59
Dopo l'orario di chiusura:
11.85
Precedente Chiudi:
$11.26
Aprire:
$11.56
Volume 24 ore:
48,114
Relative Volume:
0.45
Capitalizzazione di mercato:
$311.07M
Reddito:
$59,000
Utile/perdita netta:
$-21.81M
Rapporto P/E:
-1.082
EPS:
-10.9518
Flusso di cassa netto:
$-18.07M
1 W Prestazione:
+0.85%
1M Prestazione:
-18.67%
6M Prestazione:
+10.54%
1 anno Prestazione:
+31.81%
Intervallo 1D:
$11.55
$11.99
Intervallo di 1 settimana:
$11.02
$12.08
Portata 52W:
$7.05
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Nome
Benitec Biopharma Inc
Settore
Industria
Telefono
(510) 780-0819
Indirizzo
3940 TRUST WAY, HAYWARD, CA
Confronta BNTC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
11.85 | 295.58M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-07 | Iniziato | TD Cowen | Buy |
| 2024-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-10-16 | Iniziato | Oppenheimer | Outperform |
| 2024-09-12 | Iniziato | Guggenheim | Buy |
| 2024-07-22 | Iniziato | Leerink Partners | Outperform |
| 2024-06-13 | Iniziato | Piper Sandler | Overweight |
| 2020-10-05 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-04-20 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-02-26 | Downgrade | Maxim Group | Buy → Hold |
| 2015-12-31 | Reiterato | Maxim Group | Buy |
| 2015-09-16 | Reiterato | Maxim Group | Buy |
Mostra tutto
Benitec Biopharma Inc Borsa (BNTC) Ultime notizie
Benitec Biopharma Inc. Stock Analysis and ForecastBreakthrough investment results - Autocar Professional
What drives Benitec Biopharma Inc. stock priceMarket-crushing profits - Autocar Professional
What analysts say about Benitec Biopharma Inc. stockFree Trend-Following Techniques - jammulinksnews.com
Is Benitec Biopharma Inc. a good long term investmentSkyrocketing investment returns - jammulinksnews.com
Why Benitec Biopharma Inc. stock attracts strong analyst attentionSteady Income Ideas - Newser
(BNTC) Investment Report - news.stocktradersdaily.com
Does Benitec Biopharma Inc. stock pay reliable dividendsFree Investment Community - Newser
Benitec Biopharma Limited (NASDAQ:BNTC) Given Average Recommendation of “Buy” by Analysts - Defense World
What analysts say about Benitec Biopharma Inc. stock outlookSmart High Yield Swing Trades - Newser
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid trial progress - Investing.com Australia
How Benitec Biopharma Inc. stock performs during market volatilityFree Stock Market Entry & Exit Signals - Newser
What makes Benitec Biopharma Inc. stock price move sharplyTriple Digit Return Forecasts - Newser
Citizens JMP Reaffirms Their Buy Rating on Benitec Biopharma (BNTC) - The Globe and Mail
Benitec BioPharma stock maintains Market Outperform rating at JMP By Investing.com - Investing.com Canada
Benitec completes first cohort in gene therapy trial, advances to next phase By Investing.com - Investing.com South Africa
When the Price of (BNTC) Talks, People Listen - news.stocktradersdaily.com
Benitec Biopharma Advances BB-301 Clinical Study - TipRanks
Benitec Biopharma Provides Operational Updates - GlobeNewswire
Benitec Biopharma Inc. Provides Operational Updates - MarketScreener
Benitec Biopharma (BNTC) Moves Forward with Clinical Study Enrollment | BNTC Stock News - GuruFocus
Benitec completes first cohort in gene therapy trial, advances to next phase - Investing.com
Benitec Biopharma Inc Azioni (BNTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):